Table 5 Fetal or neonatal Outcomes, According to Study Group
From: Maternal and infant outcomes during the COVID-19 pandemic: a retrospective study in Guangzhou, China
Outcomes | 24 January – 31 March 2020 | 24 January – 31 March 2019 | P Value |
|---|---|---|---|
Median gestational age at delivery (Mean ± SD) — wk | 39.26 ± 1.42 (n = 589) | 39.08 ± 1.63 (n = 733) | 0.04* |
Full-term birth — no./total no. (%) | 560/589 (95.08) | 681/733 (92.91) | 0.77 |
Premature birth — no./total no. (%) | 29/589 (4.92) | 51/733 (6.96) | 0.15 |
Median birth weight (Mean ± SD) — kg | 3.21 ± 0.43 (n = 589) | 3.22 ± 1.32 (n = 733) | 0.86 |
Median birth length (Mean ± SD) — cm | 49.64 ± 1.81 (n = 589) | 49.45 ± 2.15 (n = 733) | 0.11 |
Low birth weight infant | 13/589 (2.21) | 19/733 (2.60) | 0.66 |
Adverse fetal | 7/589 (1.19) | 11/733 (1.50) | 0.63 |
Adverse neonatal outcomes — no./total no. (%) | |||
Admission to NICU | 122/589 (20.71) | 157/733 (21.42) | 0.80 |
Infection | 27/589 (4.58) | 59/733 (8.05) | 0.02* |
Shock | 1/589 (0.17) | 4/733 (0.55) | 0.27 |
Sepsis | 1/589 (0.17) | 5/733 (0.68) | 0.17 |
Apgar score < 7 after 1 min | 10/589 (1.70) | 20/733 (2.73) | 0.22 |
Asphyxia | 1/589 (0.17) | 1/733 (0.14) | 0.88 |
NRDS | 5/589 (0.85) | 11/733 (1.50) | 0.29 |
Patent foramen ovale | 21/589 (3.57) | 44/733 (6.00) | < 0.001*** |
Patent ductus arteriosus | 14/589 (2.38) | 17/733 (2.32) | 0.95 |
Macrosomia | 11/589 (1.87) | 25/733 (3.41) | 0.10 |
Myocardial damage | 43/589 (7.30) | 60/733 (8.19) | 0.58 |
Neonatal hyperbilirubinemia | 66/589 (11.21) | 95/733 (13.00) | 0.39 |
Hypoalbuminemia | 18/589 (3.06) | 33/733 (4.5) | 0.19 |
Hypocalcemia | 11/589 (1.87) | 24/733 (3.27) | 0.12 |
25-hydroxyvitamin D deficiency | 16/589 (2.72) | 1/733 (0.14) | < 0.001*** |
Zinc deficiency | 46/589 (7.81) | 20/733 (2.73) | < 0.001*** |
Neonatal polycythemia | 8/589 (1.36) | 3/733 (0.41) | 0.06 |
G6PD deficiency | 3/589 (0.51) | 2/733 (0.27) | 0.49 |
Caput succedaneum | 27/589 (4.58) | 26/733 (3.55) | 0.36 |